<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390686</url>
  </required_header>
  <id_info>
    <org_study_id>Samson-2</org_study_id>
    <nct_id>NCT03390686</nct_id>
  </id_info>
  <brief_title>A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prestige Biopharma Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prestige Biopharma Pte Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference
      product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and
      EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenecity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study
      in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).

      Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be
      compared between HD204 and bevacizumab.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Objective Response Rate by 24 weeks</measure>
    <time_frame>24 weeks from randomization</time_frame>
    <description>Any PR or CR prior to the 24th week will be marked as response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject</time_frame>
    <description>PFS from the date of randomisation to the date of disease progression or death up to 12 months from randomisation of the last subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from the date of randomisation to the date of death up to 12 months from randomisation of the last subject</time_frame>
    <description>OS defined as the time from Day 1 of therapy until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>from documented tumour response until disease progression up to 12 months from randomisation of the last subject</time_frame>
    <description>DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events using CTCAE v4.03</measure>
    <time_frame>AEs will be reported from the time the informed consent form (ICF) is signed until the EOT visit. The expected EOT visit for a final subject is approximately 30 months from study initiation.</time_frame>
    <description>After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Level [Ctrough] (Pharmacokinetics)</measure>
    <time_frame>Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)</time_frame>
    <description>Ctrough at selected cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] (Pharmacokinetics)</measure>
    <time_frame>Up to 21 weeks (Cycle 1,3,5 and 7. Each cycle is 21 days.)</time_frame>
    <description>Cmax at selected cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (Immunogenecity)</measure>
    <time_frame>Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days. The expected EOT visit for a final subject is approximately 30 months from study initiation.)</time_frame>
    <description>Incidence of anti-drug (bevacizumab) antibodies (ADA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibodies (Immunogenecity)</measure>
    <time_frame>Up to 21 weeks (Cycle 1,3,5, 7 and EOT visit. Each cycle is 21 days. The expected EOT visit for a final subject is approximately 30 months from study initiation.)</time_frame>
    <description>Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>HD204 (Bevacizumab biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD204 + Carboplatin/Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin (Bevacizumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avastin® + Carboplatin/Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg IV every 3 weeks on Day 1</description>
    <arm_group_label>Avastin (Bevacizumab)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HD204</intervention_name>
    <description>15 mg/kg IV every 3 weeks on Day 1</description>
    <arm_group_label>HD204 (Bevacizumab biosimilar)</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles</description>
    <arm_group_label>HD204 (Bevacizumab biosimilar)</arm_group_label>
    <arm_group_label>Avastin (Bevacizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles</description>
    <arm_group_label>HD204 (Bevacizumab biosimilar)</arm_group_label>
    <arm_group_label>Avastin (Bevacizumab)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years

          -  ECOG performance status of 0-1

          -  Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung
             cancer

          -  At least one measurable lesion according to RECIST v1.1.

          -  Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory
             and clinical parameters

        Exclusion Criteria:

          -  Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma

          -  Sensitizing EGFR mutations or ALK rearrangements

          -  Increased risk of bleeding determined by investigator based on radiographic / clinical
             findings

          -  History of systemic chemotherapy administered in the first-line setting for metastatic
             or recurrent disease of NSCLC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa S Park</last_name>
    <role>Study Chair</role>
    <affiliation>Prestige Biopharma Pte Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa S Park</last_name>
    <phone>+6569246535</phone>
    <email>lisa@pbpsg.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

